Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Holding NBIX?
Track your performance easily
NBIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.98 - $150.39
Previous Close$146.8
Volume825.99K
Average Volume (3M)759.07K
Market Cap
$14.77B
Enterprise Value$13.94B
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$375.70M
Price to Earnings (P/E)40.4
Beta0.41
Next Earnings
Aug 01, 2024EPS Estimate
$1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.64
Shares Outstanding100,637,227
10 Day Avg. Volume792,947
30 Day Avg. Volume759,072
Standard Deviation0.09
R-Squared0.05
Alpha0.00705
Financial Highlights & Ratios
Price to Book (P/B)6.17
Price to Sales (P/S)7.18
Price to Cash Flow (P/CF)27.40
P/FCF Ratio28.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.03
Enterprise Value/Gross Profit7.55
Enterprise Value/Ebitda28.02
Forecast
1Y Price Target
$165.06Price Target Upside13.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Neurocrine News
Bulls Say, Bears Say
Bulls Say
EarningsNeurocrine Biosciences has demonstrated consistent revenue growth.
PipelineThe company has a strong pipeline of drugs in development.
RegulatoryFDA accepted NBIX’s NDAs for crinecerfont for pediatric and adult patients with CAH and granted Priority Review.
Bears Say
Clinical DataShares could trade down 10-15% if the '568 Phase 2 study fails to demonstrate compelling results across any of the 4 doses tested.
Financial PerformanceManagement reduced guidance due to the removal of automatic Medicaid coverage renewals, leading to expected lower net revenues.
Product CompetitionCompetitor CRNX’s atumelnant could emerge as a market leader in CAH if early promising data prove durable and can be replicated in larger sample sizes.
---
Ownership Overview
16.10% Insiders
25.60% Mutual Funds
29.44% Other Institutional Investors
28.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $99.98 and its highest was $150.39 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Aug 01, 2024 which is yesterday.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on May 01, 2024. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.098 by -$0.678.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.13.
How many shares outstanding does Neurocrine have?
Neurocrine has 100,637,230 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $0.42 in its last earnings report, missing expectations of $1.098. Following the earnings report the stock price went up 3.992%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Dodge & Cox. It holds Neurocrine’s shares valued at 175M.
---
Neurocrine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.06 (13.64% Upside)
$165.06 (13.64% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 457.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.24%
12-Months-Change
Fundamentals
Return on Equity
18.16%
Trailing 12-Months
Asset Growth
47.15%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q1 2024
0:00 / 0:00
---
NBIX Stock 12 Month Forecast
Average Price Target
$165.06
▲(13.64% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
19/21 ratings generated profit
1 Year Average Return
+17.19%
reiterated a buy rating last month
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +17.19% per trade.
---